NextBio

Help
Description: Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.
Mechanism of Action: Irbesartan is a nonpeptide angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor. In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II. Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. Irbesartan, by blocking the binding of angiotensin II to the AT1 receptor, promotes vasodilation and decreases the effects of aldosterone. The negative feedback regulation of angiotensin II on renin secretion also is inhibited, but the resulting rise in plasma renin concentrations and consequent rise in angiotensin II plasma concentrations do not counteract the blood pressure–lowering effect that occurs.
Indication: For the treatment of hypertension, and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension.
Half Life: 11-15 hours
View Complete Description



Data Correlations | 2 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
AGTR1 100 100
ELOVL3 96 96
CAMP 87 87
SERTAD4 85 85
6530401D17Rik 85 85
CYCS 78 78
View Top Genes
Biogroups category icon Biogroups
Score Help
Globoside Metabolism 100 100
Electron Transport Reaction In Mito… 100 100
ACE Inhibitor Pathway 100 100
Glycosaminoglycan Degradation 99 99
Small Leucine-rich Proteoglycan (SL… 99 99
Blood coagulation inhibitor, Disint… 99 99
View Top Biogroups

Individual Studies

  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…

  • Studies of new selective PPAR-gamma modulators

    Mus musculus Mus musculus | RNA Expression   RNA Expression

    Expression pattern of adipocytes after telmisartan, pioglitazone or irbesartan treatment

    Authors: Witt Henning, Schupp Michael, Clemenz Markus et al.

    Organization: Max Planck Institute for Molecular Genet…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving irbesartan.

View All Author iconAuthors
  • Hans-Henrik Parving
  • M Pfeffer
  • S Hohnloser
  • Thomas Kahan
  • Peter Hovind
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Sanofi-Aventis
  • Bristol-Myers Squibb
  • Steno Diabetes Center
  • Novartis
  • Dresden University of Technology
View All Affiliations icon Organizations
  • Steno Diabetes Center
  • University of Udine
  • University of Alberta
  • CORE-Center for Outcomes Research
  • Karolinska Institutet Danderyd Hospital

Clinical Trials | 83 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “irbesartan”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

View All NextBio Groups | 1 group

© 2010 NextBio